YOLFTbeta
Clinuvel Pharmaceuticals Ltd

Clinuvel Pharmaceuticals Ltd

CUV · AU · Healthcare / Biotechnology

7.42AUD-0.22 (-2.88%)

Price History

Full chart

Market Stats

Previous Close7.64
Open7.55
Day Range7.34 – 7.57
52-Week Range7.93 – 13.40
Volume77.04K
Market Cap408.47M
P/E (TTM)12.09
Forward P/E13.32
EPS0.67
Dividend Yield0.62%
Beta0.56
50-Day Avg8.96
200-Day Avg9.98

About

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; SCENESSE and other formulations of afamelanotide to treat severe disorders, including vitiligo and porphyrias; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Philippe Jacques Wolgen M.B.A., M.D.
  • Employees0
  • Headquarters535 Bourke Street, Melbourne, VIC, Australia, 3000, Australia
  • Websitehttps://www.clinuvel.com

Leadership

  • Dr. Philippe Jacques Wolgen M.B.A., M.D.CEO, MD & Director · b. 1963
  • Mr. Peter VaughanChief Financial Officer
  • Mr. Lachlan HayChief Operations Officer
  • Dr. Dennis J. Wright BPharm, M.Sc., Ph.D.Chief Scientific Officer
  • Mr. Malcolm BullHead of Australian Operations & Investor Relations
  • Dr. Azza HamilaHead of Quality Assurance & Drug Safety
  • Ms. Claire Newstead-Sinclair C.A.Company Secretary
  • Dr. Linda TengDirector of North American Operations
  • Dr. Emilie RodenburgerDirector of Global Clinical Affairs

Financials

Income Statement

Currency: AUD2000-06-302001-06-302002-06-302003-06-302004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue140.00K409.00K258.00K136.00K355.00K124.62K754.85K283.31K4.30M2.90M1.47M1.04M722.80K1.55M2.66M3.32M6.82M16.77M25.49M31.05M32.57M47.98M65.72M78.32M88.18M95.02M94.02M
Growth (%)-+192.14%-36.92%-47.29%+161.03%-64.90%+505.71%-62.47%+1416.72%-32.39%-49.26%-29.37%-30.57%+114.86%+71.48%+24.58%+105.58%+145.81%+52.01%+21.82%+4.89%+47.32%+36.99%+19.17%+12.59%+7.76%-1.05%
Cost of Revenue176.00K71.00K81.00K75.00K86.00K190.00K114.00K957.17K945.44K916.53K466.00K57.00K52.00K166.45K372.14K5.91M1.94M615.08K949.77K445.36K14.13M12.77M19.10M27.73M7.73M15.88M15.81M
Gross Profit-----124.62K754.85K-673.86K-945.44K-916.53K-1.04M722.80K1.39M2.29M-2.59M4.88M16.15M24.54M30.60M18.43M35.20M46.62M50.59M80.45M79.14M78.21M
Gross Margin-----100.00%100.00%-237.85%-22.00%-31.55%-100.00%100.00%89.28%86.03%-78.08%71.61%96.33%96.27%98.57%56.60%73.38%70.93%64.59%91.23%83.29%83.18%
Operating Expense-----12.45M11.66M10.60M17.90M17.28M-13.77M11.03M9.67M8.12M8.24M8.43M9.35M12.32M13.91M8.23M8.51M13.53M9.68M32.44M33.40M37.68M
Operating Income--1.97M-4.18M-4.91M-8.74M-12.33M-10.90M-11.27M-18.85M-18.19M-16.38M-12.73M-10.31M-8.28M-5.83M-10.83M-3.55M6.80M12.21M16.69M10.20M26.70M33.08M40.91M48.01M45.73M40.53M
Operating Margin--480.75%-1622.00%-3608.41%-2460.64%-9893.77%-1444.27%-3979.38%-438.66%-626.23%-1111.13%-1222.93%-1425.86%-533.21%-218.91%-326.34%-52.04%40.55%47.93%53.76%31.31%55.65%50.34%52.23%54.44%48.13%43.11%
EBITDA--1.18M-3.40M-4.11M-7.94M-11.51M-9.99M-10.37M-13.81M-14.52M-10.80M-12.64M-10.24M-8.22M-5.95M-10.79M-3.74M6.85M12.26M18.35M11.99M28.19M35.08M46.37M56.28M57.20M41.11M
EBITDA Margin--289.26%-1317.34%-3024.39%-2238.02%-9232.69%-1323.09%-3659.87%-321.48%-499.88%-733.03%-1214.10%-1417.21%-529.47%-223.48%-325.35%-54.80%40.87%48.10%59.10%36.81%58.76%53.37%59.20%63.82%60.20%43.72%
Net Income--1.56M-3.14M-3.98M-7.59M-11.03M-10.77M-9.18M-14.66M-15.37M-11.52M-11.41M-9.77M-6.80M-5.53M-10.40M-3.12M7.18M13.22M18.13M16.65M24.73M20.88M30.60M35.64M36.17M33.92M
Net Income Margin--380.93%-1217.44%-2924.10%-2137.95%-8849.99%-1426.65%-3238.92%-341.07%-529.19%-781.62%-1095.95%-1351.30%-438.04%-207.50%-313.41%-45.76%42.83%51.89%58.41%51.12%51.54%31.77%39.08%40.41%38.07%36.07%
R&D1.00K462.73K373.00K949.44K5.54M5.22M4.00M4.47M6.11M9.99M7.42M7.19M4.89M4.02M2.94M231.96K133.46K129.81K53.64K91.45K341.30K547.55K1.23M1.27M2.35M7.40M18.09M
R&D as % of Total Revenue0.71%113.14%144.57%698.12%1560.18%4189.20%529.98%1577.57%142.24%343.96%503.56%690.68%676.82%259.01%110.56%6.99%1.96%0.77%0.21%0.29%1.05%1.14%1.88%1.62%2.66%7.79%19.24%
Interest Expense000000000000000000021.11K25.89K1.62M2.27M3.19M4.45M4.46M81.28K
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.07%0.08%3.37%3.46%4.08%5.05%4.70%0.09%

Balance Sheet

Currency: AUD2000-06-302001-06-302002-06-302003-06-302004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets15.44M13.77M10.52M8.07M10.25M10.06M17.07M67.82M54.97M41.61M29.51M20.17M16.00M15.81M17.15M13.64M20.14M28.61M42.90M62.35M81.54M108.57M144.81M194.52M231.12M271.75M296.15M
Total Liabilities123.54K318.26K210.83K535.45K1.39M2.60M3.08M2.43M3.16M4.56M3.08M3.76M2.36M1.98M1.73M2.44M2.30M3.16M3.49M5.17M9.48M9.83M19.25M29.89M28.11M30.94M23.27M
Total Equity15.32M13.45M10.31M7.53M8.85M7.45M13.99M65.39M51.81M37.05M26.43M16.41M13.64M13.84M15.43M11.22M17.80M25.39M39.42M57.18M72.07M98.74M125.56M164.63M203.01M240.81M272.88M
Cash7.93M6.98M4.41M2.61M5.48M4.76M8.61M33.84M25.75M21.71M19.41M12.18M12.72M12.57M14.63M10.57M13.84M23.75M36.20M54.27M25.65M37.14M27.41M23.87M183.87M224.11M20.43M
Total Debt-------------------432.52K1.32M1.30M1.26M999.87K879.78K528.53K1.94M
Net Debt-7.93M-6.98M-4.41M-2.61M-5.48M-4.76M-8.61M-33.84M-25.75M-21.71M-19.41M-12.18M-12.72M-12.57M-14.63M-10.57M-13.84M-23.75M-36.20M-53.84M-24.33M-35.84M-26.15M-22.87M-182.99M-223.58M-18.49M

Cash Flow

Currency: AUD2000-06-302001-06-302002-06-302003-06-302004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow--514.54K-2.49M--6.00M-9.25M-11.40M-8.18M-7.18M-10.99M-11.78M-9.49M-10.02M-6.89M-4.81M-4.53M-5.04M9.92M11.69M18.46M14.19M19.26M39.87M36.91M37.05M41.10M36.91M
Investing Cash Flow--78.00K-76.00K-74.83K-42.50K-1.10M-2.36M-26.47M-741.57K6.52M9.64M2.55M4.79M436.61K-3.44K-10.70K-98.05K-67.48K-75.12K-257.62K-888.83K-854.33K-434.44K-1.03M-29.03M-47.72M-39.12M
Financing Cash Flow6.94M1.00M-1.31M8.91M9.63M17.60M60.02M1.05K143.61K-1.50K-5.76M6.27M6.88M222.70K8.39M85.08K-1.03M-1.03M-1.49M-1.48M-1.50M-2.24M-3.57M-2.94M-2.75M
Capital Expenditure100.00K78.00K76.00K74.83K42.50K1.10M362.61K440.50K221.11K32.45K45.16K69.53K4.50K30.85K3.44K12.10K98.05K67.48K75.12K257.62K888.83K854.33K434.44K1.03M5.58M298.57K1.60M
Free Cash Flow--592.54K-2.57M-74.83K-6.05M-10.35M-11.77M-8.62M-7.40M-11.02M-11.83M-9.56M-10.03M-6.92M-4.81M-4.54M-5.13M9.85M11.62M18.20M13.30M18.41M39.44M35.88M31.48M40.80M35.31M
Dividends Paid----------------0957.16K957.16K957.16K1.22M1.24M1.24M1.98M2.47M2.50M2.51M
FCF to OCF-115.16%103.05%-100.71%111.90%103.18%105.39%103.08%100.30%100.38%100.73%100.04%100.45%100.07%100.27%101.95%99.32%99.36%98.60%93.74%95.56%98.91%97.22%84.95%99.27%95.66%
Dividend Paid to FCF----------------0.00%9.72%8.24%5.26%9.20%6.71%3.13%5.51%7.85%6.14%7.10%

Earnings

Report DateFeb 22, 2016Aug 29, 2016Feb 24, 2017Aug 30, 2017Feb 27, 2018Aug 29, 2018Feb 25, 2019Aug 28, 2019Feb 26, 2020Aug 27, 2020Feb 24, 2021Aug 31, 2021Feb 23, 2022Aug 30, 2022Feb 24, 2023Feb 26, 2025Aug 27, 2025Feb 23, 2027
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.230.220.290.240.260.51-
EPS Actual-0.070.000.050.090.030.250.090.270.020.300.130.340.120.280.220.280.44-
Surprise-----------51.11%-44.70%-3.11%-7.56%8.11%-13.21%-
Timing---------After-hours---After-hoursPre-market-Pre-marketPre-market

Key Statistics & Ratios

Market Cap408.47M
Enterprise Value166.42M
Trailing P/E12.09
Forward P/E13.32
PEG Ratio0.65
Price / Sales4.34
Price / Book1.53
EPS0.67
Book Value5.41
Revenue (TTM)94.02M
Gross Profit (TTM)78.21M
EBITDA41.11M
Profit Margin36.07%
Operating Margin47.32%
Return on Equity13.21%
Return on Assets8.94%
Shares Outstanding50.43M
Shares Float44.03M
Beta0.56
Dividend Yield0.62%
Dividend Rate0.05
Payout Ratio7.49%

Ownership Breakdown

Institutions
10.01%
Insiders
16.59%
Retail / Other
73.40%

Top Fund Holders

  • Vanguard International Stock Index-Total Intl Stock Indx
    647.83K1.31%
  • Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund
    246.59K0.50%
  • iShares Core MSCI EAFE ETF
    182.27K0.37%
  • iShares MSCI EAFE Small Cap ETF
    177.67K0.36%
  • College Retirement Equities Fund-Stock Account
    112.16K0.23%
  • DFA Asia Pacific Small Company Series
    108.28K0.22%
  • Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index
    95.63K0.19%
  • Bernstein Fund, Inc.-International Small Cap Portfolio
    87.49K0.18%
  • Schwab Strategic Tr-Schwab International Small Cap Equity ETF
    53.64K0.11%
  • DFA International Core Equity Portfolio
    42.85K0.09%

Dividends

20261×
0.05Sep 3, 2026
20251×
0.05Sep 4, 2025
20241×
0.05Sep 5, 2024
20231×
0.05Sep 5, 2023
20221×
0.04Sep 6, 2022
20211×
0.03Sep 2, 2021
20201×
0.03Sep 3, 2020
20191×
0.03Sep 4, 2019
20181×
0.02Sep 21, 2018

Stock Splits

  • Nov 11, 20101:10